Clinical Laserthermia Systems

7.59 SEK

+2.85 %

Less than 1K followers

CLS B

First North Stockholm

Medical Equipment & Services

Health Care

Overview

Financials & Estimates

Ownership

Investor consensus

+2.85 %

-12.96 %

-35.79 %

+161.27 %

+107.38 %

+79.01 %

-85.03 %

-97.20 %

-96.92 %

Clinical Laserthermia Systems operates in the medical technology sector. The company's vision is to develop and streamline the treatment of solid cancer tumors, where the company is a seller of sterile patient kits. The products are used in various cancer treatments such as in the treatment of malignant melanoma, as well as cancer of the lungs, liver and pancreas. The company was founded in 2006 and has its headquarters in Lund.

Market cap

236.55M SEK

Turnover

289.92K SEK

Revenue

18.78M

EBIT %

-288.87 %

P/E

-

Dividend yield-%

-

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

20.2

2026

Annual report '25

15.5

2026

Interim report Q1'26

14.8

2026

Interim report Q2'26

All

Press releases

ShowingAll content types

Regulatory press release12/3/2025, 7:30 AM

CLS: Clinical Laserthermia Systems Submits CE-Marking Application for its ClearPoint Prism[®][ ]branded Neuro Laser Therapy System seeking European Regulatory Approval for use in Neurosurgery

Clinical Laserthermia Systems

Press release11/17/2025, 8:32 AM

Redeye: CLS Q3 (Review) - Soft sales, but better quarters ahead

Clinical Laserthermia Systems

Regulatory press release11/14/2025, 7:30 AM

CLS Publishes Interim Report January - September 2025

Clinical Laserthermia Systems

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release10/7/2025, 8:15 PM

CLS-sponsored neuro LITT study in patients with malignant brain tumor shows positive results

Clinical Laserthermia Systems

Regulatory press release9/30/2025, 11:35 AM

CLS: Clinical Laserthermia Systems AB Raises SEK 20.9 Million Through Full Subscription of Warrants of Series TO 8 B

Clinical Laserthermia Systems

Regulatory press release9/4/2025, 3:00 PM

CLS: Clinical Laserthermia Systems Receives FDA Clearance for Expanded Labeling of the ClearPoint Prism[®] Neuro Laser Therapy System, doubling the addressable U.S market for Neuro LITT

Clinical Laserthermia Systems

Press release8/25/2025, 9:20 AM

Redeye: CLS Q2 - Strong report that reinforces confidence in outlook

Clinical Laserthermia Systems

Regulatory press release8/22/2025, 6:30 AM

CLS publishes half-year report January - June 2025

Clinical Laserthermia Systems

Regulatory press release6/27/2025, 2:35 PM

CLS: Communique from the Annual General Meeting on Friday June 27th in Clinical Laserthermia Systems A

Clinical Laserthermia Systems

Regulatory press release6/6/2025, 7:00 PM

CLS: Clinical Laserthermia Systems publishes annual report for 2024

Clinical Laserthermia Systems

Regulatory press release5/27/2025, 9:00 AM

CLS: Notice of Annual General Meeting of Clinical Laserthermia Systems AB June 27, 2025

Clinical Laserthermia Systems

Press release5/19/2025, 11:19 AM

Redeye: CLS Q1 - A solid quarter largely in line with our expectations

Clinical Laserthermia Systems

Regulatory press release5/16/2025, 6:30 AM

CLS: Clinical Laserthermia Systems AB publishes Interim report for January - March 2025

Clinical Laserthermia Systems

Regulatory press release4/28/2025, 6:30 AM

CLS: Clinical Laserthermia Systems, together with its partner ClearPoint Neuro, announces FDA submission to expand the labeling of ClearPoint Prism® to include 1.5 T MRI guidance

Clinical Laserthermia Systems

Regulatory press release4/15/2025, 6:30 AM

CLS: Updated clinical guidelines provide clear recommendations on the use of Laser Interstitial Thermal Therapy (LITT) in patients with metastatic brain tumors and radiation necrosis

Clinical Laserthermia Systems

Press release4/9/2025, 2:56 PM

BioStock: CLS not significantly affected by tariffs

Clinical Laserthermia Systems

Regulatory press release4/8/2025, 11:45 AM

Proposed U.S. tariffs expected to have minimal impact on CLS business

Clinical Laserthermia Systems

Press release2/27/2025, 11:16 AM

BioStock: CLS raises up to 37 MSEK through directed share issue

Clinical Laserthermia Systems

Regulatory press release2/27/2025, 7:55 AM

CLS: Clinical Laserthermia Systems AB raises up to SEK 37m through a directed issue for accelerated commercialization and expansion

Clinical Laserthermia Systems

Press release2/25/2025, 11:14 AM

BioStock: CLS continues toward the goal of becoming cash flow positive by 2026

Clinical Laserthermia Systems

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.